《新股消息》荃信生物-B(02509.HK)今起招股 一手入場費4,081元
內地針對自身免疫及過敏性疾病生物療法的臨床階段生物科技商荃信生物-B(02509.HK)公開招股,擬全球發售1,204.64萬股,香港公開發售佔約一成,國際發售佔九成。招股價介乎每股19.8至20.2元。每手200股計,一手入場費4,080.75元。該股今日(12日)起招股,周五(15日)中午截止,預期下周三(20日)掛牌。獨家保薦人為中金。
公司上市引入3名基石投資者,包括股東泰州健鑫旗下健鑫醫藥、華東醫藥(000963.SZ)旗下華東投資及蜂投資本,合共認購2,500萬美元公司股份。
如以招股價中位數20元計,公司上市料淨集資約1.64億元,當中約30.1%擬分配至核心產品QX002N的開發及註冊;約54.6%用於其他核心產品QX005N的開發及註冊;約8.7%用於QX004N的開發及註冊;約1.9%用於QX006N的臨床試驗(包括試驗地點、CRO及受試者入組的成本)、QX006N準備註冊文件以及CMC成本;約4.7%用於若干其他資產(包括QX007N、QX010N及QX013N)的研發和藥物發現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.